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Introduction
&&Academic titles (Dr.) added for authors ; OK?&& Inflam-
mation is a biological response to injury that provides protec-
tion against infection. However, if inflammation is left unregu-
lated, as can occur in disease, it can lead to severe tissue injury
and dysfunction.[1,2] Ameliorating inflammation in disease
states depends on the active control of inflammatory media-
tors such as the platelet-activating factor (PAF, 1; Figure 1).
Phospholipid 1, first reported over 45 years ago, is one
member of a family of structurally related phospholipid signal-
ing molecules.[3–5] PAF mediates inflammatory pathways, and
can exert its effects at concentrations as low as 1012m, which
makes it the most potent member of its family.[6, 7] Other bio-
molecules can also exert PAF-like activity, acting as agonists to
the PAF receptor (PAFr), including oxidized low-density lipopro-
tein, bacterial lipopolysaccharide, and lipotechoic acid moieties
in the cell walls of Streptococcus species.[8]
The PAFr is a G-protein-coupled receptor that has been a
therapeutic target for many years.[3, 4,9] PAF is an agonist of
PAFr. When PAF binds to PAFr, it induces the mitogen-activated
protein kinase (MAPK) pathway, leading to a pro-inflammatory
cascade. PAF receptors are present throughout the body, in
most major organ tissues, the central nervous system (CNS),
muscles and inflammatory cells.[1,10–13] In 2002, the PAFr gene
was localized to chromosome 1p35-1p34.4.[14] Although there
have been a number of attempts to determine the structure of
the PAFr and its binding site using molecular modeling meth-
ods, both still remain unknown.[15,16] However, work has fo-
cused on elucidating PAF binding by using radiolabeled spe-
cies such as [3H]PAF and [3H]WEB 2086, a PAFr antagonist.[9, 17]
Melnikova and Bar-Eli[8] and Peplow[18] have provided detailed
accounts of the mechanisms involved in PAF production and
receptor binding.
The production and biosynthesis of PAF have been exten-
sively studied, and a large range of cells, tissues, and signaling
pathways have been implicated in PAF-mediated inflammation.
PAF-producing cells are often white blood cells or other cells
involved in inflammation. However, hepatocytes, keratinocytes,
osteoclasts, renal mesangial cells, and vascular smooth muscle
are also reported to provide molecule 1.[1, 9, 19, 20] A large
number of diseases and disorders are associated with the in-
flammatory actions of PAF and its receptor, including cancers,
respiratory and neurodegenerative diseases. However, PAF has
been implicated in over 40 disease states.[9, 21,22]
This review discusses PAFr antagonists that demonstrate po-
tential for the treatment of inflammatory diseases, their activity
against a range of disease states, progress in the synthesis of
PAFr antagonists, and structure–activity relationships that have
been established. The last comprehensive review of PAF antag-
onists was reported in 1994.[9] For this reason, this review fo-
cuses on providing an overview of progress in this area over
the preceding 20 years.
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Platelet-activating factor (PAF) and its receptor (PAFr) have
been implicated in a wide range of diseases and disorders that
originate from the activation of inflammatory pathways. Al-
though the exact structure of the binding site on the PAFr re-
mains unknown, the PAFr is a well-established therapeutic
target, and an array of structurally diverse PAFr antagonists
have been identified. These include compounds that are struc-
turally similar to the natural PAF ligand, synthetic heterocycles,
complex polycyclic natural products, and various metal com-
plexes. This review provides an update on more than 20 years
of progress in this area. The development and synthesis of
new PAFr antagonists, structure–activity relationship studies,
the biological activity of these molecules, and their therapeutic
potential are discussed.
Figure 1. Platelet-activating factor (PAF).
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Inflammatory Diseases
Cancer remains one of the leading causes of death world-
wide.[23] It is accepted that an inflammatory microenvironment
and angiogenesis (the formation of new blood vessels), are
both important factors in cancer initiation and progres-
sion.[8,24–29] Considerable research has focused on investigating
the role that PAF and its receptor play in cancer, and both
have been specifically implicated in breast, prostate, and skin
cancer, in addition to Kaposi’s sarcoma and melanoma meta-
stasis.[8, 24,30] Consequently, this suggests that some anti-inflam-
matory drugs such as non-steroidal anti-inflammatory drugs
(NSAIDs) and PAFr antagonists could be used to treat certain
types of cancer.[24] In addition, the PAFr has been implicated in
modulating radiation and cisplatin sensitivity in various can-
cers, including prostate, cervical, and ovarian cancers.[31–33]
Inflammatory diseases of the respiratory system include
chronic obstructive pulmonary disease (COPD), which is de-
fined as chronic airflow obstruction that is progressive and
only partly reversible and which comprises emphysema and
chronic bronchitis.[34] This disease usually develops over a
number of years after routine exposure to oxidative stress,
often from cigarette smoke. However, genetic triggers and air
pollution are other possible factors.[24] Typically, irritation by
fine particles in the air elicits an inflammatory immune re-
sponse.[35,36] Bacterial and viral infections of the respiratory
tract can also trigger these immune responses; in particular,
Streptococcus, Haemophilus, and Pseudomonas species have the
capacity to directly interact with the PAFr.[37–39,8] Consequently,
the upregulation of PAFr expression on airway epithelial and
alveolar cells in smokers and COPD patients could provide a
gateway to respiratory infections.[40,41]
Mallia and co-workers provide a detailed account of the res-
piratory microbiome and the bacterial exacerbations that can
occur.[42] Current treatments include short-acting bronchodila-
tors and inhaled corticosteroids, with antibiotics often used in
conjunction to treat cases of bacterial exacerbation.[43,44] These
treatment methods mainly focus on alleviation of symptoms,
and there are obvious limitations associated with the use of
steroids and antibiotics for long-term treatment.[42,44] PAFr an-
tagonists could be used to decrease the incidence of bacterial
infection and reduce exacerbations.[15]
The role of PAF in asthma is well established. Specifically,
PAF has been implicated in the pathogenesis of asthma by in-
ducing bronchospasms, increasing vascular permeability, and
activating inflammatory cells in the lower airways.[45] The func-
tion of PAF in these biological pathways and disease progres-
sion is well documented.[45–47] The inflammatory process associ-
ated with bronchial asthma is complex and requires treatments
that target various steps in the inflammatory cycle, including
binding of the PAFr. For example, several antagonists of the
PAFr have been tested for asthma in various assays with mixed
results.[45–47] &&Refs. [45–47] OK?&& PAF has been implicat-
ed in other allergic disorders, such as anaphylaxis and allergic
rhinitis. Although the relevance of PAF is well established in
the pathophysiology of these diseases, there has been limited
research exploring the role that PAFr antagonists might play in
treating these diseases.[48] Given the increasing incidence of al-
lergic disorders, further studies are required in this area.[49]
PAF has been implicated in tissue injuries and cell death in
the spinal cord and glial cells, in neuronal apoptosis, synaptic
plasticity, and its role in oxidative stress can reportedly lead to
neural cell death.[50,51] PAF receptors are present in the brain,
on synaptic membranes, and on intracellular membranes in
the cerebral cortex. The interplay between glutamate receptors
in the CNS and PAF has also been established.[52–54] Interesting-
ly, neurodegenerative disorders such as Alzheimer’s disease
(AD) have been identified as conditions that are mediated by
PAF.[54,55] In the early stages of AD, treatment with the PAFr an-
tagonists ginkgolides A and B has demonstrated a beneficial
effect in the prevention of synapse loss and cognitive de-
cline.[55] This work has also been extended to include prion-in-
duced synapse degeneration.[56,57] In addition, it has been sug-
gested that some PAFr antagonists are capable of crossing into
the CNS and, thus, could be used in the treatment of Parkin-
son’s disease, which shares some characteristics with AD.[58]
In 2014, researchers succeeded in exploiting the PAFr path-
way to facilitate the entry of small interfering RNA oligonucleo-
tides (siRNA) into difficult-to-transfect, well-differentiated
airway epithelial cells.[59] The efficient delivery of siRNA is a
major challenge in the advancement of RNA interference tech-
nology, particularly to the airways. This study took advantage
of the existing mechanisms that microorganisms may use to
enter epithelial cells, such as the direct interaction of phos-
phorylcholine (ChoP) molecules on the surface of Streptococcus
species or non-typeable Haemophilus influenzae (NTHi) with the
PAFr. In this way, these often-detrimental invasion mechanisms
were used to facilitate entry of siRNA oligonucleotides. This
novel work demonstrates that binding of the PAFr may be
used to exploit RNA interference technology in the treatment
of lung disease or to protect against pathogens.
Besides the well-established pro-inflammatory effects of PAF,
in select cases, PAFr has also been implicated in damping the
immune response, inducing immune suppression.[60] Several in
vitro and in vivo studies have reported that the PAFr activation
in macrophages and dendritic cells is able to shift these cells
toward an anti-inflammatory or tolerogenic phenotype.[61–63]
Thus, PAFr antagonists may have the ability to fine-tune the
innate and adaptive immunity with a potential role in immuni-
zation.[62]
PAFr Antagonists
PAFr antagonists are molecules that are capable of binding to
the PAF receptor. These antagonists may competitively or non-
competitively displace PAF, the naturally occurring agonist,
from its binding site on the PAFr.[24] A wide variety of mole-
cules exhibit PAFr antagonistic activity, which can be grouped
into four broad categories: structurally related synthetic PAF
derivatives, synthetic compounds without structural similarity
to PAF, natural products, and metal complexes.[64] The majority
of the most important antagonists were synthesized prior to
1995.[9] Subsequent research has generally focused on refining
the activity of these lead compounds and testing them in vari-
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ous animal and human assays. More recent studies have pri-
marily sought to clarify and improve the synthetic routes lead-
ing to these antagonists. With this in mind, only a brief sum-
mary of key PAFr antagonists is provided below. Reviews by
Koltai and Braquet[9] and Whittaker,[65] published over 20 years
ago, already provide detailed information on many PAFr antag-
onists.
Structurally related synthetic PAF derivatives
PAF (1) contains a long alkyl tail and a quaternary ammonium
head (Figure 1). In 1983, thiazolium derivative CV-3988 (2), a
zwitterionic species similar in structure to PAF, was the first
synthetic substance identified as a PAFr antagonist, (Fig-
ure 2A).[66] This led to the preparation of a range of related de-
rivatives.[9, 65] Most examples feature a carbamate group as the
ether isostere and the lipophile is often a C16 to C18 alkyl
chain.[67] The key structural elements of this family of com-
pounds are depicted in Figure 2B. These antagonists are gen-
erally not orally active, and some suffer from toxicity
issues,[68,69] which have limited their therapeutic utility.[65,70]
Other synthetic molecules
Since the discovery of benzodiazepines as bioactive molecules,
many similar compounds have been developed. Within this
category are the hetrazepine antagonists; much attention has
been directed to replacing the fused benzene ring in the ben-
zodiazepines with other fundamental heterocyclic motifs such
as pyrazole, imidazole, pyrrole, or indole.[66] One thienodiaze-
pine, brotizolam (3), was found to inhibit PAF-induced platelet
aggregation selectively and at relatively low concentrations
when compared with other antagonists (Figure 3).[71] Further
work led to the development of WEB 2086 (apafant, 4) and
WEB 2170 (bepafant, 5), which are even more potent than bro-
tizolam.[17,72] Both compounds 4 and 5 exhibit good in vitro ac-
tivity and excellent bioavailability, with long-lasting pharmaco-
logical effects.[9] WEB 2086 is an effective PAFr antagonist in
humans, and no significant side effects have been identified
that may prevent clinical trials.[71] Indeed, molecule 5 reported-
ly featured in a number of clinical trials that were later discon-
tinued.[65,73–75] The reasons for this are unclear. The synthetic ac-
cessibility of the requisite fused diazepine ring system has
complicated the large-scale synthesis of lead compound 5.
In 1991, three more potent analogues of WEB 2086 were
identified; however, their potencies still do not compare well
with that of the natural ligand PAF.[76,77] Interestingly, while pat-
ents exist for WEB 2086 and brotizolam, there are limited spec-
troscopic data for either compounds 3 or 4 (or their known an-
alogues) in the peer-reviewed scientific literature. Indeed, the
1H and 13C NMR spectroscopic data for brotizolam were only
published in 2013,[78] and, to our knowledge, extensive spectro-
scopic data for WEB 2086 are not available.
While the diazepine core structure provides potency and ac-
tivity for PAFr antagonists, other heterocyclic scaffolds are
more synthetically accessible. The imidazo[4,5-c]pyridyl frame-
work is a particularly important motif, with key substituents
present at either the 1- or 5-positions of this subunit. An im-
portant example is UK-74,505 (modipafant, 6 ; Figure 4). Ana-
logues of modipafant have been constructed by replacing the
dihydropyridine structure with benzodiazepine, benzazepine,
and other more lipophilic moieties.[9] Various benzimidazole
structures have also shown activity, and modifying the lipophi-
licity of the substituents on these compounds provides a
marked effect on antagonist activity. Interestingly, some of the
most active benzimidazole-containing antagonists, such as
SDZ series 7, bear a close resemblance to the diazepine core
of the WEB compounds, with three fused rings comprising the
core structure.[9]
Natural products
The ginkgolides, isolated from Gingko biloba, are the most
well-studied natural products that have been identified as PAFr
Figure 2. A) CV-3988 (2). B) Key structural elements present in structurally re-
lated synthetic PAF derivatives.
Figure 3. Brotizolam (3), WEB 2086 (apafant, 4), and WEB 2170 (bepafant, 5).
Figure 4. UK-74,505 (modipafant, 6) and SDZ compounds 7.
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antagonists.[9] As a representative example, ginkgolide B
(BN 52021, 8) shows particular potency for the PAFr
(Figure 5).[79] Unfortunately, the ginkgolides are not selective
antagonists of the PAFr and have been shown to influence
other biological functions.[65] Furthermore, the generally low
natural abundance and complex structures of the ginkgolides
has limited their accessibility, and this has hindered efforts to
extensively evaluate their therapeutic potential. In addition, a
number of marine natural products, compounds of microbial
origin, and Chinese medicinal herbs have shown PAFr activity.
These include kadsurenone (9), phomactin A (10), and a range
of xanthones 11.[9, 80–82] Some other natural substances (mix-
tures or extracts) also display PAFr antagonism, including olive
oil and fish oil.[24]
Metal complexes
Recently, various rhodium complexes have been synthesized
that display activity against the PAFr.[16,83] Specifically, square
planar rhodium(I) complexes 12 and 13 and a series of rhodiu-
m(III) complexes, including representative compounds 14,
were evaluated as PAFr antagonists (Figure 6). It was deter-
mined that their activities were similar to that of WEB 2170 (5),
one of the more potent antagonists.[83] Rhenium complex 15
was also found to be active against the PAFr. Interestingly, this
molecule was also evaluated for antitumor activity, and found
to be more effective than cisplatin.[84] A range of other metal
complexes have also been evaluated for their PAFr activity.[16]
Structure–Activity Relationship (SAR) Studies
Structure–activity relationship (SAR) studies are central to the
development of potent and selective PAFr antagonists, particu-
larly as the structure of the PAFr active site remains unknown.
In silico modeling studies have identified some key features of
the PAFr binding site, but crystallographic data and protein
structural modeling are required to accurately elucidate the
binding properties of the PAFr.[15,85–88] It has been proposed
that the binding site of the PAFr consists of a bipolarized cylin-
der 10–12  in diameter, and a second, shorter domain 6–
7  in diameter.[89,90] Recent reports even suggest that the
binding site may consist of a tetrapolarized cylinder.[90] Work
has also been undertaken toward the design of a pseudo-re-
ceptor.[91] It appears that the PAFr contains a large lipophilic
binding pocket that can accommodate considerable steric
bulk, a hydrogen bond donor that can interact with either a
carbonyl or oxygen atom, and a functional group capable of
interactions with pyridine-like moieties.[89] However, these data
were obtained through a variety of different (human and
animal) assays and may not translate directly to the viability of
these compounds for the treatment of human disease.[92]
Organic small molecules
Significant research over the past decade has generated SAR
data for non-diazepine-based synthetic molecules and some
natural products.[89,90,93–96] In contrast, seminal SAR studies re-
lating to diazepine-type compounds were reported over 25
years ago, and there have been few major developments since
this time.[9,65] Heterocyclic N-substituents (possible hydrogen
bond acceptors) have been identified as crucial to providing
active PAFr antagonists. The spatial orientation of this sp2-hy-
bridized nitrogen atom appears to influence activity. Three
common heterocyclic scaffolds present in PAFr antagonists
that contain sp2-hybridized N-substituents are fused triazole
moieties (e.g. , WEB 2086), 3-pyridyl groups, and fused imida-
zole derivatives.[65]
More recently, 24 conformationally strained PAFr analogues
16 were synthesized (Figure 7A).[89] These molecules share
some structural similarities with PAF. Specifically, these com-
pounds consist of various combinations of lipophiles and N-
heterocycles joined via a hydrogen bond acceptor such as an
ether or a carbamate group, which were linked to cyclic frame-
works such as 1,1-bis(hydroxymethyl)cycloalkanes or 3,3-bis(hy-
droxymethyl)oxetanes, -thietanes, and -azetanes. All of these
analogues were found to be potent antagonists of PAFr, with
greater activity than CV-6209 (17) and ginkgolide B (8).
Although thietanes 16 provided superior activity in some in-
stances, in the majority of cases the presence of a heteroatom
in the four-membered ring made little difference. Ring size did
affect potency, but a discernable trend was not evident. The
Figure 5. Ginkgolide B (BN 52021, 8), kadsurenone (9), phomactin A (10),
and xanthones 11.
Figure 6. Metal complexes 12–15.
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identity of the counter-anion was not significant ; however, car-
bamates did appear slightly more active than ethers. The
nature of the heterocyclic nitrogen atom provided the greatest
influence on potency, with quinolones having been found to
be the most potent, followed by thiazoles and pyridines. Qua-
ternization of compounds appeared crucial, as neutral synthet-
ic precursors displayed much lower activities.[89]
A number of new trisubstituted 4-aminopiperidines 18 were
prepared as alternatives to previously reported piperazine an-
tagonists (Figure 8).[65,90] These heterocycles featured improved
conformational flexibility and greater distances between the
key N-substituents. All of the molecules in this series contained
a trimethoxybenzyl group (TMB), which is present in known
PAFr antagonists (e.g. , SDZ series 7).[65] SAR data revealed that
the replacement of the piperazine core with the aminopiperi-
dine motif did not change the ability of molecules to bind the
PAFr. Although there were marked differences in PAFr binding
activity associated with various diastereomers used in this
study, a clear trend was not evident.[90]
Novel ginkgolide derivatives have been primarily accessed
via semi-synthesis, and this has facilitated SAR studies of this
class of compounds. In the ginkgolide series, a tert-butyl group
appears to be critical for providing notable biological activity
(Figure 9).[9] Rings E and F are also essential for the retention of
activity.[94,95] However, substitution of the hydroxy group on
lactone ring F with lipophilic moieties, such as substituted
benzyl groups, does not have a significant effect.[95] The pres-
ence of B ring-substituents typically increases the ability of the
molecules to bind the PAFr.[95] Furthermore, 7-a-substituted
ginkgolides generally feature higher affinity for the PAFr than
the corresponding 7-b-derivatives; 7-a-chloroginkgolide B is
the most potent derivative described.[95] Interestingly, ginkgoli-
de C (19), which differs from ginkgolide B (8) by the presence
of a 7-hydroxy group, is 25-fold less potent than the latter.[95]
Various xanthones 11 were assessed for their ability to inhib-
it the effects of PAF (Figure 10). It was determined that a R6-
prenyl group features strong binding affinity for the PAFr, but
when this group is hydroxylated, activity is lost. Cyclization of
the R6-prenyl group to deliver chromene 20, which is annulat-
ed at the 5- and 6-positions, provided only slightly lowered po-
tency (as did the presence of a R8-dimethylprop-2-enyl sub-
stituent; Figure 10). However, chromene 21, annulated at the
2,3-positions provided a small loss in binding affinity. The pres-
ence of a R1-phenolic substituent increased potency, while the
presence of a R2-hydroxy group had the opposite effect.[82]
Metal complexes
Some metal-based complexes have been assessed for their
anti-inflammatory activity.[97] However, limited research has in-
vestigated applications of metal-based compounds as PAFr an-
tagonists. Some studies have provided preliminary SAR data re-
garding coordination geometry, ligand substitution, the effects
of the counter-anions and the overall size and charge of the
complex. A range of rhodium(III) complexes featuring biden-
tate ligands have been prepared (e.g. , complexes 14 ;
Figure 6).[16,83] Molecular modeling studies illustrated that octa-
hedral complexes containing two aromatic ligands are unable
to fit into the PAFr binding site and, hence, any observed activ-
ity occurs via nonspecific binding.[16] Various square planar rho-
dium(I) complexes were also prepared (e.g. , complexes 12 and
13 ; Figure 6).[83] Biological assays evaluating the inhibition of
PAF-induced platelet aggregation and theoretical docking
Figure 7. A) Conformationally strained PAFr analogues 16. B) CV-6209 (17).
Figure 8. Examples of 4-aminopiperidine-based PAFr antagonists 18.
Figure 9. Ginkgolide B (8) and ginkgolide C (19).
Figure 10. Xanthones 11 and annulated chromene derivatives 20 and 21.
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studies illustrate that these compounds are selective and
potent inhibitors.[83] All of the square planar rhodium com-
plexes prepared as part of this study were more active than
rhodium analogues featuring octahedral coordination geome-
tries.[16, 83]
Copper(II), zinc(II), cobalt(II), nickel(II), and gallium(II) com-
plexes containing chalcogenated imidodiphosphinato ligands
are PAFr antagonists (Figure 11).[98,99] These complexes feature
a range of fundamental metal coordination geometries, with
the bulkiest gallium complex 24a identified as the most active
of these molecules. A range of ruthenium(II/III) complexes, in-
cluding compounds 24b and 24c, were also synthesized and
evaluated as PAFr antagonists.[16] The activity of these com-
plexes increased dramatically upon exchanging the chloride
for a hexafluorophosphate counter-anion. In addition, ionic
compounds were typically found to be more active than their
neutral analogues.[16]
Synthesis of PAFr Antagonists
A variety of structurally diverse molecules have been identified
as PAFr antagonists, and an array of approaches have been de-
veloped to prepare them. However, over the past 20 years, the
focus of research in this area has primarily centered on improv-
ing the synthetic accessibility of established diazepine-based
antagonists. During this period, the synthesis of original metal-
based antagonists was also notable.
Synthetic heterocycles
Compounds containing the 1,4-diazepine motif exhibit a broad
range of biological activity, including PAFr antagonism, and are
traditionally used as sedatives.[100] Examples include alprazolam,
clonazepam, diazepam or lorazepam, among others. The most
common approaches to the construction of these benzodiaze-
pine drugs involve multistep pathways in which protected a-
amino acids are coupled with an o-ketoaniline, deprotected,
and then cyclized. These methods feature poor atom economy
and can be complicated by racemization at the a-stereogenic
center.
In 2017, a direct method enabling stereospecific, single-step
syntheses of benzodiazepine core structures was reported
(Scheme 1).[101] This method featured the reaction of chiral N-
carboxyanhydrides (NCAs, 25) with o-ketoanilines 26 to effi-
ciently provide enantiopure diazepinones 27 (with water and
carbon dioxide as the only byproducts). Notably, products 27
did not require purification using this approach. This strategy
avoids issues associated with earlier routes, which were com-
plicated by lengthy and low-yielding syntheses, low atom
economy, and difficulties constructing the key seven-mem-
bered heterocyclic core.[102–105] Unfortunately, the synthesis of
NCAs 25 typically requires triphosgene or phosphorus trichlor-
ide and, consequently, this method is perhaps not well suited
to synthesis on industrial scales.[101] Although the transforma-
tion shown in Scheme 1 has enabled the synthesis of com-
pounds related to WEB 2086 and WEB 2170, these specific mol-
ecules have not been prepared by this approach.[101]
Thiophenes can act as effective bioisosteres for benzene,
(e.g. , in benzodiazepine drugs).[106] The thiophene analogues
are generally less well studied than traditional benzodiazepine
congeners. The early PAFr antagonists WEB 2086 (4) and
WEB 2170 (5) contain a thienodiazepine core (Figure 3), as do
other related drugs already on the market, such as etizolam or
clotiazepam.[66,107] Notably, the use of a thiophene in place of a
benzene could serve to overcome the selectivity issues that
have been associated with the benzodiazepine drugs.
The benzodiazepine scaffold is known to interact with vari-
ous receptors in the body, making it an excellent structure to
use in drug development; however, this also means that there
are risks of off-target effects.[106] Consequently, efforts have
been directed at improving the synthesis of thienodiazepine
scaffolds to investigate their therapeutic potential.[100] To this
end, recent work has strived to establish more viable synthetic
approaches that are shorter, more efficient, and are amenable
to scale-up.[108]
The synthetic accessibility of thienodiazepines, such as
WEB 2086 (4), has improved. Specifically, a number of patents
concerning the synthesis of brotizolam (3, a precursor of
WEB 2086) and its analogues have been filed, most recently in
2012.[103,109–112] Brotizolam can be synthesized in six to eight
steps (Scheme 2).[113] The majority of these processes require
relatively hazardous reagents and are complicated by rather
time-intensive procedures and typically low-yielding transfor-
mations.
Figure 11. Copper(II), cobalt(II), zinc(II), nickel(II), gallium(II), and ruthenium
complexes 22–24.
Scheme 1. Synthesis of diazepinones 27: (i) 2 equiv TFA, PhMe, 60 8C, then
2 equiv NEt3, 80 8C.
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Naik et al. reported an improved 75–80% yield over the last
three synthetic steps by slightly modifying established chemis-
try.[103] Many of the intermediate compounds also appear diffi-
cult to purify.[113] The four steps, shown in Scheme 2, are repre-
sentative of general approaches. In this case, the reaction of 2-
aminothiophene 28 with a 2-halogenated acetyl halide, such
as bromoacetyl bromide, afforded amide 29. Subsequent cycli-
zation formed heterocycle 30, and the installation of the tria-
zole was then completed over two steps to furnish brotizolam
(3).
It appears that the order of the steps in the above-men-
tioned reaction sequence leading to the key seven-membered
ring can be varied.[110, 113] Although most reports illustrate that
acid catalysts and high temperatures are necessa-
ry,[71,105,110, 114,115] a patent suggests that bases, such as sodium
hydroxide or triethylamine, can also catalyze these transforma-
tions.[116] In addition, it has been noted that cyclizations can
occur spontaneously.[117] Installation of the triazole ring has
been effected using a number of different reagents, usually by
treatment of amide 30 with a chlorination or thionation agent,
and then reaction with a hydrazide or hydrazine.[103,105,110,112, 114]
A series of novel 1,4-thienodiazepine-2,5-diones 34, 18 in
total, were synthesized via four-component Ugi reaction/ de-
protection sequences from thiophenes 31 (Scheme 3).[100, 118]
This two-step Gewald process has been used for preparing
these heterocycles for many years,[110] and has been used in
the synthesis of WEB 2086 (4) and analogues.[71,119] The four-
component Ugi condensation reaction has not been used pre-
viously to access this manifold and offers an efficient route to
thienodiazepines and the ability to introduce up to six points
of diversity into the products.[100, 118] By using this strategy, the
successful synthesis of thieno[2,3-e][1,4]diazepines was estab-
lished by a sequence commencing from proline derivatives
and 2-aminobenzenethiols or dithiandiol.[95,120] For example, a
Gewald reaction provided heterocycle 35 (Scheme 4), which
was then transformed into a thienopyrimidinone and alkylated
to deliver tricycle 36. The seven-membered ring was formed
via a one-pot base-mediated hydrolysis/N-alkylation/cyclization
transformation to afford product 37.[121] The biological activity
of compound 37 has yet to be evaluated.
The majority of thienodiazepine-based PAFr antagonists
such as WEB 2086 (4) feature 2-amino-fused thiopheno-1,4-dia-
zepines 38 (Figure 12). In contrast, 3-amino-fused congener 39
has not been the subject of significant interest. Heterocycles of
this type were first prepared via the condensation of 3-thiaisa-
toic anhydride with l-proline in 1998.[122] These frameworks
have been constructed by the one-pot regioselective ring
opening of 3-thiaisatoic anhydride 41 using chiral a-amino
acids 40, followed by intramolecular condensation to afford
heterocycles 42 (Scheme 5).[120,123] This method is also amena-
ble to solid-phase synthesis using Wang resin, and in this way,
eight analogues were prepared in 71–95% yields.[124] While
these regioisomeric thienodiazepines have not been tested as
PAFr antagonists, these structures have demonstrated activity
Scheme 2. Synthesis of brotizolam (3): (i) 1.1 equiv bromoacetyl bromide,
1 equiv pyridine, Et2O, RT; (ii) 1:1 CH2Cl2/ NH3(l), reflux, then DMSO, 100 8C;
(iii) 1.4 equiv NaN3, DMSO, RT, then H2, Pd/C, AcOH; (iv) 1 equiv P2S5, pyridine,
reflux, then AcOH, 3 equiv methylhydrazine, nBuOH, reflux.
Scheme 3. Synthesis of 1,4-thienodiazepine-2,5-diones 34 : (i) 1 equiv ethyl
glyoxylate, MeOH, RT; (ii) TFA, RT, then 1,5,7-triazabicyclo[4,4,0]dec-5-ene,
NEt3, THF, 40 8C.
Scheme 4. Synthesis of thieno[2,3-e][1,4]diazepines 37: (i) 2 equiv MeCN, di-
oxane/HCl, 40 8C; (ii) 3 equiv K2CO3, 1.1 equiv ethyl bromoacetate, DMF, RT.
Figure 12. 2-Amino-fused thiopheno-1,4-diazepinone 38 and 3-amino-fused
1,4-diazepinone 39.
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against other receptors. As previously noted, the spatial orien-
tation of molecules in PAFr antagonists does influence receptor
binding.[65] Thus, it is possible that regioisomeric thienodiaze-
pines, such as molecules 42, may represent potential PAFr an-
tagonists.
A series of thienodiazepinones 45 and various thienopyridi-
nones 46 were prepared from precursors 43 (Scheme 6A).[107]
Heterocycles 45, which are structurally similar to PAFr antago-
nists WEB 2086 (4) and WEB 2170 (5), were synthesized by a se-
quence featuring the addition of aryl Grignard nucleophiles 44
to substrates 43a, Boc-group deprotection, Schiff base con-
densation, and oxidative deprotection. In contrast, compounds
46 were efficiently prepared by the nucleophilic addition of re-
actants 44 to heterocycles 43b followed by a two-step intra-
molecular aldol condensation. In 2015, Pictet–Spengler reac-
tions were used to construct a library of 24 novel thienodiaze-
pines 48 (Scheme 6B).[67] In this work, a-amino acids were cou-
pled with 3-aminothiophenes to provide substrates 47, and
Pictet–Spengler reactions furnished heterocycles 48.[67] By this
approach, a series of phenylalanine-, alanine-, and proline-
based analogues were prepared.[67]
A range of thienopyrimidines 49, thienotriazones 50, and
thienodiazepinones 51 have been prepared from 2-aminothio-
phenes by standard methods (Figure 13).[125] These compounds
featured potent antitumor properties, but have not been spe-
cifically tested for activity toward the PAFr. In addition, the
Beckmann rearrangement was used to construct various thie-
noazepines 52, furanoazepines 53, pyrroloazepines 54, and
thienodiazepines 55.[126] Many of these molecules were identi-
fied as vasopressin antagonists and antitumor agents, but
have not been specifically tested for PAFr activity. These previ-
ously unreported compounds all contain clear structural simi-
larities to existing PAFr antagonists and guide the develop-
ment of new PAFr antagonists.
Pyrrolodiazepines represent alternative scaffolds to both
benzodiazepines and thienodiazepines. The majority of estab-
lished methods to these systems use Pictet–Spengler reactions
to convert 1-[2-(a-aminoalkyl)phenyl]pyrroles into these tar-
gets.[127] However, the arylpyrrole starting materials featured in
these transformations are susceptible to decomposition in the
presence of acids and other electrophilic agents, which poten-
tially limits their utility.[127] In 2010, a novel approach was devel-
oped that obviates the need for using arylpyrrole substrates
(Scheme 7).[127] The method converts furans 56 directly into
heterocycles 57 in a single step.
Pyridine-fused compounds 61 were synthesized from pyri-
dines 58 and amino acids 59 (Scheme 8).[128] Importantly, inter-
mediates 60 do not require further functionalization prior to
conversion into cyclized products 61. In contrast, germane
conventional approaches do require additional functional
Scheme 5. Synthesis of 3,4-substituted thieno[2,3-e][1,4]diazepine-2,5-diones
42 : (i) H2O, 40 8C, then AcOH, reflux.
Scheme 6. A) Synthesis of thienodiazepinones 45 and thienopyridinones 46 :
(i) THF, RT; (ii) 1:1 TFA/CH2Cl2, RT; (iii) NEt3 ; (iv) 5 equiv CAN, 3:1 MeCN/H2O,
RT; (v) THF, RT; (vi) 2.2 equiv KOtBu, THF; (vii) 4.4 equiv p-TsOH. B) Synthesis
of thienodiazepine compounds 48 : (viii) PhMe, 4  molecular sieves, 110 8C.
Figure 13. Representative thienopyrimidines 49, thienotriazinones 50, thie-
nodiazepinones 51, thienoazepines 52, furanoazepines 53, pyrroloazepines
54, and thienodiazepines 55 that have been synthesized.
Scheme 7. Synthesis of pyrrolodiazepines 57: (i) 7:1 AcOH/HCl, RT.
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group manipulations prior to construction of the diazepine
ring. For example, transformation of amines 59 into 1,3-oxa-
zine-2,6-dione derivatives or the Boc-protection/acylation of
amines 59.[117, 128] It is unknown whether these pyrrolo- and pyr-
idine-fused compounds act as PAFr antagonists similar to
thieno- and benzodiazepine analogues.
Other PAFr antagonists
The first total syntheses of ()-ginkgolides A and B were com-
pleted in 1988 by Corey et al.[129] Over a decade later, a 25-step
total synthesis of ()-ginkgolide B (8) was disclosed, which
showcased an original stereoselective intramolecular photocy-
cloaddition reaction.[79]
Total syntheses of phomactin A (10), phomactin D (62), pho-
mactin B2 (63), and phomactin G (64) have been completed
(Figures 5 and Figure 14).[130,131] Phomactin A has been pre-
pared a number of times. This natural product has been ac-
cessed via an intramolecular Suzuki–Miyaura cross-coupling
and Nozaki–Hiyama–Kishi-type macrocyclizations.[130a–c] The
centerpiece of another approach to molecule 10 featured an
original intramolecular oxa-[3+3] annulation.[130d,e] Compound
62 was prepared stereoselectively from ascorbic acid, phomac-
tin B2 (63) was synthesized via the intramolecular annulation
of a chromium carbene, and target 64 was realized by an intra-
molecular Nozaki–Hiyama–Kishi reaction.[131]
A number of xanthone natural products have been pre-
pared, including elliptoxanthone A, tovophyllin B, the aglycone
analogue of IB-00208, and a- and b-mangostin.[132] Total syn-
theses of kadsurenone (9) have been reported (Figure 5).[133]
Notably, Popinom et al. prepared molecule 9 in only three
steps from allyloxyphenol and 3,4-dimethoxycinnamyl alcohol
by developing a novel pericyclic cascade reaction.[133a] Over a
decade later, a biomimetic synthesis of this natural product
was reported.[133b]
Finally, several patents have been published on the synthesis
and use of PAFr antagonists. These include the synthesis of
ginkgolide analogues, 2,5-diaryltetrahydrothiophenes, tetrahy-
drofurans, and 1,3-diarylcyclopentanes and their applications
in the treatment of PAF-associated conditions including cardio-
vascular, inflammatory, and immune disorders.[134–138] In addi-
tion, a range of sulfamoylheteroaryl pyrazole anti-inflammatory
agents have been prepared,[139] and various cyclohexylsulfona-
mide compounds have also been developed for use as PAFr
antagonists.[140]
A number of molecules have also been synthesized that are
structurally similar to existing PAFr antagonists ; however, these
compounds have not been tested for PAFr activity. These in-
clude pyrrolo[1,4]thienodiazepines, furano-, thieno-, and pyrro-
lazepines, pyrrolo-, indolo, benzo-, and thieno[1,4]diazepines,
thineodiazepinones, thienotriazolo[1,4]diazepines, substituted
triazolodiazepines, thienopyrimidine, thienopyridine, thieno-
thiazine, and thienoxazine and 2-amino-3-aroyl-4,5-alkylthio-
phenes. Among these classes of compounds, various ana-
logues have been identified as human adenosine receptor in-
hibitors and bromodomain inhibitors.[141–152] Metal-based PAFr
antagonists have typically been prepared via standard meth-
ods.[83,103,153]
Conclusions and Outlook
PAF is implicated in over 40 different disease states. Specifical-
ly, PAF and its receptor are involved in many biological func-
tions involving inflammatory processes, including cancer, lung
diseases and neurodegeneration. Despite this, specific thera-
peutic applications of PAFr antagonists are somewhat limited.
A range of structurally diverse classes of molecules have
been demonstrated to serve as PAFr antagonists. Synthetic
strategies for construction of the more complex antagonists
have evolved, and new efficient methods have been devel-
oped over the past 20 years, particularly in the case of diaze-
pine-based antagonists. SAR studies have been conducted on
many of these molecules, and some key properties have been
identified. Indeed, many PAFr antagonists feature sp2-hybrid-
ized nitrogen substituents with appropriate spatial orientations
in addition to lipophilic groups. A number of metal-based
complexes have recently demonstrated potent PAFr antagonis-
tic activity. Indeed, some are more effective than cisplatin in
the treatment of tumors, which suggests that these com-
pounds may feature other interesting biological activities.
While detailed SAR data can assist in designing and identify-
ing lead compounds, crystallographic and protein structural
modeling are crucial to pinpointing the key PAFr amino acid
residues involved in ligand binding, and the development of
Scheme 8. Synthesis of heterocycles 61: (i) 10% KOH/H2O, DMF, 50 8C;
(ii) neat, 220 8C.
Figure 14. Phomactin D (62), phomactin B2 (63), and phomactin D (64).
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highly specific and potent antagonists. Consequently, advances
in the latter areas are crucial moving forward.
The structurally related synthetic PAF derivatives show good
potency and selectivity but suffer from issues of toxicity and
bioavailability. Hence, subsequent studies have shifted away
from these molecules to focus on heterocyclic structures.
While a number of these diazepine-based compounds are very
potent and selective antagonists, there are concerns regarding
their potential side effects due to the presence of the diaze-
pine motif, in addition to their somewhat limited synthetic ac-
cessibility. More recently, heterocyclic compounds that do not
contain diazepine cores have emerged as effective antagonists.
Natural products that exhibit PAFr antagonism are often not
selective and arguably feature limited therapeutic potential.
PAF and the PAFr and their role in biological functions have
been investigated in detail, and there is now a solid basis for
exploring therapeutic strategies involving these molecules.
Over the past 20 years, a range of new compounds have been
prepared, which represent potent and specific antagonists,
such as the regioisomeric thienodiazepines. In the future, exist-
ing (and new) PAFr antagonists which show promise in in vitro
cell-based assays and in vivo animal models should be further
investigated with regard to their therapeutic potential and
candidacy for advancement to clinical trials.
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